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National malaria management policy is based upon the availability of eﬀective and aﬀordable antimalarial drugs. This study was
undertaken to evaluate the quality of the treatment of uncomplicated malaria cases in Bangui, an area with multidrug-resistant
parasites,atatimeprecedingimplementationofanewtherapeuticpolicyrelyingontheartemisininderivativecombinedtreatment
artemether-lumefantrine. A cross-sectional study was carried out in Bangui city to assess availability of antimalarial drugs and the
performances of health workers in the management of uncomplicated malaria. Availability of drugs was recorded in all drugs
wholesalers (n = 3), all pharmacies in health facilities (n = 14), private drugstores (n = 15), and in 60 non-oﬃcial drug shops
randomly chosen in the city. Despite a limited eﬃcacy at the time of the survey, chloroquine remained widely available in the
oﬃcial and nonoﬃcial markets. Artemisinin derivatives used in monotherapy or in combination were commonly sold. In health
care facilities, 93% of the uncomplicated malaria cases were treated in the absence of any laboratory conﬁrmation and the oﬃcially
recommended treatment, amodiaquine-sulfadoxine/pyrimethamine, was seldom prescribed. Thus, the national guidelines for the
treatment of uncomplicated malaria are not followed by health professionals in Bangui. Its use should be implemented while a
control of importation of drug has to be reinforced.
1.Background
The aim of malaria management policy is to provide ther-
apeutic guidelines to health workers and eﬃcacious and
aﬀordable drugs to health facilities for patients to buy. This
policy must be based on proper laboratory diagnosis and
treatment of malarial episodes.
Given the rapid evolution of parasite resistance to
chloroquine and sulfadoxine-pyrimethamine (SP), several
countries have modiﬁed their national policy and adopted
the artemisinin derivative combined treatments (ACT’s) as
recommended by WHO [1].
Access to drugs is widely available for the urban popu-
lation through private drugstores and an illicit market [2].
The consequence is an increase of “drugs pressure” on the
parasite strains, thus increasing the risk of development of
multidrug resistance [3] .M o r e o v e r ,u r b a nm a l a r i ah a si t s
own epidemiological characteristics requiring appropriate
ﬁghting methods [4].
In Bangui, capital of Central African Republic (CAR),
chloroquine is no longer recommended by the National
Malaria Control Program (NMCP) because the resistance
rate was of 40.9% in 2004 [5], while, in rural areas, this
rate has been estimated to be around 15% [6]. As a
matteroffact,theartemether-lumefantrin(AL)combination
should be implemented within a year from the period
when this study is conducted. Thus, in the meantime,
the amodiaquine and sulfadoxine-pyrimethamine (AQ/SP)
association has been adopted as the ﬁrst line treatment since
year 2003.2 Journal of Tropical Medicine
Table 1
Sample population: drugs sellers categories Data collection method Sample size
Generic drugs wholesalers (UCM,
CENTRAPHARM and ROFFE-PHARMA)
Interview/questionnaire/assessment
of availability 3 (exhaustive sample)
Health facilities Interview/questionnaire/assessment
of availability 14 (exhaustive sample)
Private pharmacies (“Drugstores”) Interview/questionnaire/assessment
of availability 15 (exhaustive sample)
Drug vendors on the illicit market (city shops) Assessment of availability
(investigator behaved as a client) 60 shops randomly chosen across the city
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Figure 1: Location of Bangui, Central African Republic.
This study, conducted in 2006, reports the availability of
antimalarial drugs in health facilities, drugstores, and illicit
market, as well as the attitude of health workers for the
diagnostic and treatment of uncomplicated malaria cases in
health facilities in Bangui.
2. Methods
2.1. Study Area and Setting. This survey was carried out
between May and July 2006 in Bangui, the capital of Central
African Republic. The location of this city is shown in
Figure 1.
This city is located on the Oubangui River which
separates CAR from the Democratic Republic of Congo (4◦
North, 19
◦ East). The climate is subequatorial with a rainfall
period between April and November and temperatures
varying from 19
◦Ct o3 2
◦C. This city of 620,771 inhabitants
is subdivided in eight districts and represents 16.0% of the
CAR population. Health care is provided by 14 small public
healthfacilities,4privatedispensaries,and3publichospitals.
According to the NMCP guidelines, the management of an
uncomplicated malarial episode is as follows: (i) clinical
presumption of malaria, (ii) conﬁrmation by microscopic
diagnosis on blood ﬁlm, and (iii) administration of the rec-
ommended ﬁrst line treatment (currently AQ/SP). Quinine
remains the ﬁrst line antimalarial drug for pregnant women
and the drug of choice for complicated malaria cases.
Malaria transmission is perennial, with a peak during
the rainy season and is hyperendemic. In order to control
the drug distribution chain, importation of all health
products is submitted to a registration by the Ministry
of Health and Population. As reported by the National
Oﬃce of Medicines, two main categories of wholesalers are
allowed to import generic drugs: a public centre (“Unit´ ed e
CessionduM´ edicament,”UCM)andtwoprivatewholesalers
(CENTRAPHARM and ROFFE-PHARMA). UCM has been
created following the Initiative of BAMAKO in 1987. It
imports aﬀordable generic drugs which are distributed to the
health facilities. Additionally 17 private pharmacies import
also drugs directly from various international wholesalers.
2.2. Sampling Methods and Data Collection. Our method of
survey of the drugs providers is detailed in Table 1.
In the city shops, from the illicit market, interviewer
asked for the availability of antimalarial drugs. The investi-
gator had acted as a client and no questionnaire was ﬁlled
up.
Assessmentofuncomplicatedmalariatreatmenthasbeen
achieved at all of the fourteen public health facilities and
three private dispensaries of Bangui, where a questionnaire
was used to collect data.
For all patients who had had a diagnosis of uncompli-
cated malaria and exit, an interview and a checking of their
health notebook was done to know the way of obtaining
diagnosis (laboratory conﬁrmed or presumptive diagnosis)
and which treatment has been prescribed. At the end of
the day, health workers who were in charge of malaria
patients were interviewed using a qualitative questionnaire.
The theoretical knowledge and practical attitudes towards
the content of the NMCP guidelines were collected.Journal of Tropical Medicine 3
In order to minimize the Hawthorne eﬀect (the Haw-
thorne eﬀect is deﬁned as a “positive and temporary
change in some measurable behavior in a situation where
the observer had no intention to truly aﬀect the other
individual’sbehavior”)[7]inmalariamanagementpractices,
in each health facility the assessment was only performed in
one day.
2.3. Data Analysis. Data were entered and analyzed on
EpiInfo software 3.3.2, (Centers for Disease Control and
Prevention, Atlanta, USA). The results were presented as
proportions.
2.4. Ethical Approval. The complete study protocol was
accepted, duly registered, and approved by the CAR Min-
istry of Health and Population, Malaria division. An oral
informedconsentwasgivenbyallinterviewedparticipantsat
the oﬃcial drug market and health facilities. For the purpose
of this study, the nonsoﬃcial drug sellers were kept blind of
the investigator intention, as they would have been reluctant
to disclose information because their activity is considered as
illegal in CAR.
3. Results
3.1.AntimalarialDrugsAvailabilityinBangui. InBangui,the
type of antimalarial drug availability depends widely upon
the category of provider (Table 2).
Amodiaquine, sulfadoxine-pyrimethamine, artemether,
halofantrine, and quinine were available from the three
generic drugs wholesalers. Two ACT’s combinations: ar-
tesunate-sulfamethoxypyrazine-pyrimethamine (Coarinate)
and artemether-lumefantrine (Coartem) were available in
two private wholesalers’ stores.
SP, and Q were available from all “oﬃcial” drug
providers.Drugstoressoldthecompletepanelofantimalarial
drugs including chloroquine which was absent from whole-
salers and health centers. CQ was also widely present in the
illegal market, while AQ, SP and Q are sometimes available.
Drugstores were the only place where Art-C were present.
However it has to be noted that AT was widely available on
the oﬃcial market despite the recommendation to not use it
alone.
3.2. Therapeutic Practice for Uncomplicated Malaria. Among
42 patients treated for uncomplicated malaria, only three
(7.1%) were prescribed antimalarial drug based upon
microscopy results. Recommended AQ/SP was prescribed
only in 14.3% of cases (Figure 2).
A total of 18 health workers out of 25 (72%) conﬁrmed
that they prescribed treatment in the absence of laboratory
diagnosis arguing that fever is strongly associated with
malaria in an endemic area, and such an attitude allows to
exclude for the patient thick and thin blood ﬁlm cost which
is oﬃcially charged 0.76 USD.
7.1% (3)
2.4% (1)
2.4% (1)
7.1% (3)
14.3% (6)
66.7% (28)
Quinine
Amodiaquine
Amodiaquine +
sulfadoxine/pyrimethamine
Halofantrine
Artemether
Sulfadoxine/pyrimethamine
Figure 2: Types of prescription of antimalarial drugs in Bangui
health facilities, May–July 2006 assessment.
A basic knowledge of the oﬃcial guidelines was reported
for 10 out of 23 health workers (44%) regarding children, 13
out of 20 (65%) regarding pregnant women and 14 out of 25
(56%) regarding other categories of patients.
4. Discussion
The survey has shown that the management of malaria is
not satisfactory because a wide range of antimalarial drugs
remains available in Bangui city, distributed among the
oﬃcial and illicit market, and the poor quality of service
oﬀered in health centres.
Although chloroquine is no longer oﬃcially recom-
mended and has been withdrawn from the public health
facilities, it remains available in drugstores and city shops.
Despite a loss of eﬃcacy [5, 6], it is still widely used because
it is the cheapest antimalarial drug available, and, because
it was given the status of intermediate resistance in CAR,
since it is active against malaria symptoms without curing
parasitemia.
The illicit drug market is generalized in developing
countries [8, 9]a st r a ﬃcking across the borders is poorly
controlled. The price of drugs found in such market is
attractive (these drugs are often product of poor quality and
of a dubious origin) and they are retailed as tablets for 1
single treatment [10, 11]. In India, Das and Hammer noted
that the private market encourages inadequate treatments
whatever can be the competence of the providers [12].
In 2006, WHO asked for the withdrawal of artemisinin
as monotherapy, used in Bangui, as it may be responsible
for a rapid emergence of resistance [1] which would impair
its future use in combination therapies. However, it remains
available in Bangui where it is commonly used as a therapeu-
tic option.4 Journal of Tropical Medicine
Table 2: Number of providers of antimalarial drugs in Bangui, May to July 2006 assessment.
Provider (Total) AQ AT CQ Art-C HA SP Q
Generic drugs at wholesalers (n = 3) 3 3 — 2 3 3 3
Generic drugs sold at pharmacies at health facilities (n = 14) 14 3 — — — 14 14
Drugstores (n = 15) 11 13 14 14 11 15 15
Non oﬃcial drugs shops or illicit market (n = 60) 11 — 42 — — 10 11
AQ: Amodiaquine, AT: Artemether, CQ: Chloroquine, Art-C: Artemether Combinations, HA: Halofantrine, SP: Sulfadoxine-Pyrimethamine, Q: Quinine.
Many factors hamper the changing of therapeutic habits
and henceforth the adoption of international recommen-
dations. Changing the national malaria treatment policy is
challenging and costly. In Tanzania, for instance, replacing
chloroquine with SP would require 4 percent of the annual
government budget [13]. The diversity of antimalarial drugs
available is also an obstacle to the success of the national
malaria treatment policy [14]. Thus the number of available
drugs should be limited and people should be informed of
the reason for such a policy.
Attendance in health facilities was very low at the time
of the study (42 cases of uncomplicated malaria diagnosed).
According to health workers, defection of the community
for health facilities is due to the costs of consultation and
treatment as they consider that fever is always associated
with malaria. Thus self-medication or drugstore counseling
is favoured.
The absence of microscopic conﬁrmation is a common
practice among health workers in Bangui as well as in
others developing countries. This attitude is of concern as
there is no algorithm for malaria treatment based solely on
clinical examination [15]. As reported in other countries
[16], systematic treatment is given to minimize the cost
for patients with limited income. However, according to a
study in Malawi, which compared systematic treatment to
microscopic conﬁrmation, the latter attitude would allow
annual savings of 17,472 USD per medical facility [17].
Legal and universal medical practice implementation
requires validated speciﬁc training before allowing health
workers to consult and prescribe drugs. Nevertheless, in
developing countries like CAR, due to lack of qualiﬁed
practitioners, paramedics are receiving in-service training
and are then considered capable of taking medical decisions.
It have been reported that theoretical skill alone has little
impact on practical behaviour when dealing with malaria
patients [18], and that ﬁnancial incentives to practitioners
do not lead to an improvement in quality of health whereas
ongoing training organized by health authorities has a
signiﬁcant one [12].
5. Conclusion
Our study indicates that the treatment of malaria was poorly
handled in the health facilities of Bangui in 2006. The
availability of antimalarials on the illegal market without
any assurance about their quality and the fact that health
workers do not follow the oﬃcial guidelines are obstacles
to the success of the government’s policy for the control of
malaria. Chloroquine should be withdrawn from CAR drug
market.
Training, information, and participation of health pro-
fessionals to decision making are a key to improve adherence
to new protocol guidelines. Results from this study and other
investigations conducted in other countries highlight the
need to consider speciﬁc implementation guidelines since
most African countries have now adopted ACT’s combi-
nation therapies. Considering that artemether-lumefantrine
and artesunate-amodiaquine have been made available
for ﬁrst line treatment since the beginning of 2007 in
CAR (NMCP 2008 reports), ongoing evaluations of the
compliance of health workers to the new guidelines are
indispensable as well as the acceptation of these drugs by the
population.
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